» Articles » PMID: 17822928

Role of Lipid Rafts in the Processing of the Pathogenic Prion and Alzheimer's Amyloid-beta Proteins

Overview
Date 2007 Sep 8
PMID 17822928
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The conformational conversion of the cellular form of the prion protein (PrP C) into the infectious form (PrP Sc) and the proteolytic processing of the amyloid-beta (Abeta) peptide are central pathogenetic events in the prion diseases and Alzheimer's disease, respectively. Cholesterol- and sphingolipid-rich lipid rafts have emerged as important sites for the conversion of PrP C into PrP Sc, and for the proteolytic production, degradation and aggregation of Abeta. Here, we discuss these findings and their implications for our understanding of these disease processes. In addition, the potential for rafts as sites for therapeutic intervention in prion diseases and Alzheimer's disease is considered.

Citing Articles

Antimicrobial Peptides Increase Line Tension in Raft-Forming Lipid Membranes.

Koynarev V, Borgos K, Kohlbrecher J, Porcar L, Nielsen J, Lund R J Am Chem Soc. 2024; 146(30):20891-20903.

PMID: 39018511 PMC: 11295182. DOI: 10.1021/jacs.4c05377.


Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer's Disease.

Faraji P, Kuhn H, Ahmadian S J Mol Neurosci. 2024; 74(3):62.

PMID: 38958788 PMC: 11222241. DOI: 10.1007/s12031-024-02224-4.


Heart fatty acid-binding protein is associated with phosphorylated tau and longitudinal cognitive changes.

Fu Y, Wang Z, Huang L, Tan C, Cao X, Tan L Front Aging Neurosci. 2022; 14:1008780.

PMID: 36299612 PMC: 9588952. DOI: 10.3389/fnagi.2022.1008780.


Efficient calculation of the free energy for protein partitioning using restraining potentials.

Kwon S, Pantelopulos G, Straub J Biophys J. 2022; 122(11):1914-1925.

PMID: 35962549 PMC: 10257010. DOI: 10.1016/j.bpj.2022.07.031.


The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2.

Garrido P, Calvelo M, Blanco-Gonzalez A, Veleiro U, Suarez F, Conde D Int J Pharm. 2020; 588:119689.

PMID: 32717282 PMC: 7381410. DOI: 10.1016/j.ijpharm.2020.119689.